Acute arthritis and arthralgia as an adverse drug reaction to dupilumab

Clinical and Experimental DermatologyVolume 45, Issue 2 p. 262-263 Viewpoints in dermatology ● Correspondence Acute arthritis and arthralgia as an adverse drug reaction to dupilumab L. E. M. de Wijs, orcid.org/0000-0001-6801-0828 Department of, Dermatology, Erasmus University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorJ. D. van der Waa, Department of, Dermatology, Erasmus University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorP. H. P. de Jong, Department of, Rheumatology, Erasmus University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorD.J. Hijnen, Corresponding Author d.hijnen@erasmusmc.nl orcid.org/0000-0003-3379-3425 Department of, Dermatology, Erasmus University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this author L. E. M. de Wijs, orcid.org/0000-0001-6801-0828 Department of, Dermatology, Erasmus University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorJ. D. van der Waa, Department of, Dermatology, Erasmus University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorP. H. P. de Jong, Department of, Rheumatology, Erasmus University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this authorD.J. Hijnen, Corresponding Author d.hijnen@erasmusmc.nl orcid.org/0000-0003-3379-3425 Department of, Dermatology, Erasmus University Medical Center, Rotterdam, The NetherlandsSearch for more papers by this author First published: 19 July 2019 https://doi.org/10.1111/ced.14050Citations: 12 LEMdW and JDvdW contributed equally to this work and should be considered joint first authors. Conflict of interest: DH has been an investigator for AbbVie, LEO Pharma, MedImmune/Astrazeneca, Novartis and Sanofi/Regeneron, and held consultancies for Regeneron/Sanofi, LEO Pharma, MedImmune/AstraZeneca, Novartis, Incyte, Janssen and Pfizer. The other authors declare that they have no conflicts of interest. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume45, Issue2March 2020Pages 262-263 RelatedInformation